您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Voruciclib
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Voruciclib
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Voruciclib图片
规格:98%
分子量:469.8
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
Voruciclib 是一种具有口服活性的选择性 CDK 抑制剂,Ki 值为 0.626 nM-9.1 nM。 Voruciclib 有效阻断 CDK9,MCL-1 的转录调节因子。 Voruciclib 在多种弥漫性大 B 细胞淋巴瘤 (DLBCL) 模型中抑制 MCL-1 的表达。
货号:ajcx20336
CAS:1000023-04-0
分子式:C22H19ClF3NO5
分子量:469.8
溶解度:Soluble in DMSO
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Voruciclib is a pan-inhibitor of cyclin-dependent kinases (CDKs; Kis = 0.626-9.1 nM).1 It is selective for CDKs over male germ cell associated kinase (MAK) and intestinal cell kinase (ICK; Kis = 259 and 481 nM, respectively), in a panel of 48 kinases. Voruciclib decreases myeloid cell leukemia-1 (Mcl-1) levels and increases cleaved poly(ADP-ribose) polymerase (PARP) levels in six diffuse large B-cell lymphoma (DLBCL) cell lines when used at concentrations ranging from 0.5 to 5 μM. It reduces tumor growth by 56.3% in a Ri-1 mouse xenograft model when administered at a dose of 200 mg/kg.


|1. Dey, J., Deckwerth, T.L., Kerwin, W.S., et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk diffuse large B-cell lymphoma to BCL2 inhibition. Sci. Rep. 7(1), 18007 (2017).